Core Insights - Azenta, Inc. has announced a strategic partnership between GENEWIZ and Form Bio to enhance adeno-associated virus (AAV) gene therapy development through an integrated sequencing and data analysis solution [1][2] Group 1: Partnership Details - The collaboration combines GENEWIZ's next-generation sequencing services with Form Bio's AI-driven analysis pipelines, aiming to provide gene therapy developers with insights into AAV capsid contents, thereby improving safety, efficacy, and manufacturability [2][3] - GENEWIZ will handle the synthesis and packaging of transgene expression cassettes, while Form Bio will perform AAV Genome Integrity Characterization using its Long-read AAV Analysis (LAAVA) software [3][4] Group 2: Benefits of the Partnership - The integration of sequencing, vector design, and development workflows is expected to reduce time and costs in reaching lead candidates, accelerating the market entry of innovative therapies [3][4] - The partnership is designed to simplify AAV gene therapy workflows, enabling researchers to make more informed decisions and overcome traditional hurdles in gene therapy development [4] Group 3: Launch and Presentation - The partnership will officially launch at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2025, where both companies will exhibit and present a poster on their collaborative work [4]